Menu
Innovative medicines through next generation targeted delivery.
Versatile platform for disease prevention and therapeutics.

Diverse
Molecules

Proteins, Peptides, Oligos and mRNA targets as immunogens and active drugs

Unique
ACM Delivery

‘Plug and play’ polymer-based delivery platform for targeting

Next Geneneration
Medicines

Targeted Vaccines, immunotherapies and unmet diseases

Our Technology

ACM stands for
Artificial Cell Membranes.


Our proprietary technology is based on polymer encapsulation vesicles which we call Artificial Cell Membranes (“ACMs”). These ACMs are nanoscale vesicles which are made from di-block or tri-block copolymers. For more than 15 years of intensive R&D we have perfected, and patented, techniques of making these ACMs and incorporating payloads within their walls such that these molecules are stable and correctly presented to elicit strong immune responses. We have shown these ACMs to have numerous advantages for the encapsulation of multiple molecule classes such as mRNA, protein, peptides and oligonucleotides.

Our proprietary polymer-based delivery platform enables packaging of mRNA, protein, peptides and/or oligonucleotides, and keeps the payload stable at 4°C. This ACM technology has the potential to revolutionize the delivery to cells and tissues.

The potential to revolutionize the delivery to cells and tissues.

At ACM Biolabs we are focused on developing novel vaccines. Our lead program, ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine ready to move into Phase I. We have a preclinical stage personalized cancer vaccine and are building up projects based on mRNA therapeutics.

With all the available functional handles, we believe that our polymer-based vesicles can be functionalized to specifically deliver payloads to target cells and tissues. With this we would have a powerful tool to address a broad range of diseases beyond infectious diseases and cancer.

We develop next generation vaccines.
1.
Our delivery is targeted to antigen-presenting cells. These dendritic cells are best suited to educate the immune system in an elegant way against virus antigens. Therefore, only low amounts of payloads in the polymersomes are needed.
2.
Polymer based delivery are made up of few components, which self-assemble and encapsulate proteins, peptides, and mRNA. An easy manufacturing process allows formation of large quantities of bulk product.
3.
Our payload is protected at refrigerator temperatures. We can store mRNA at 4°C making storage and transport much easier.

Company

Advancing ACM platform for targeted delivery.

We are based in two world leading innovation hubs for biotechnology: Singapore and Switzerland. Embedded in a rich ecosystem of pharmaceutical companies, biotechs, academic institutes and institutional and private investors, we believe this is a valuable success factor to advance our science and pipeline programs. Our experienced team with senior ex-pharma veterans provide a basis to attract talent, partners and investors.

What we do

As a dedicated team combining pharmaceutical industry, biotech, and academic excellence we develop prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment based on our proprietary ACM delivery platform technology.

Why we do it

We believe in challenging the status quo of targeted delivery in medicines and we are revolutionizing the new medicines with ACM platform. We develop these transformative medicines to treat or prevent diseases in a safe and well tolerable way.

Founded in Singapore in 2013, ACM Biolabs has established laboratories for research and early manufacturing activities. ACM Biolabs is well connected in the academic and biotechnology ecosystem.

In 2020 ACM Biosciences was established in Basel, Switzerland to internationalize its development activities. ACM Biosciences leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners. ACM Biosciences is a subsidiary of ACM Biolabs.

Investors

ACM Biolabs is backed by government bodies, investment companies and strategic corporate investors:

  • San Pacific Investment
  • Ritz Venture Capital
  • Nagase
  • NTUitive

The Team.

Show only:
Madhavan Nallani
details
Madhavan Nallani
Founder | Chief Executive Officer | Chief Scientific Officer
Director of the Board ACM Biolabs & ACM Biosciences

Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering (IMRE, A*STAR) and also at Nanyang Technological University).

Alexander Breidenbach
details
Alexander Breidenbach
Chief Development Officer | Chief Business Officer

Pharmacologist and Business Developer with more than 20 years of partnering, R&D, and management experience in pharma. Doctorate in Veterinary Sciences, EMBA from ESSEC Paris & Mannheim Business School. Expertise in business development as Roche VP and Global Head Neuroscience, Ophthalmology, Rare Diseases Partnering, Deal Team Leader and Due Diligence Director. Global Head Safety Pharmacology at Roche Pharmaceuticals. Senior Pharmacologist at Schwarz Pharma AG.

Christopher Tay
details
Christopher Tay
Chief Commercial Officer

Doctoral Degree (DBA) in the international business, MBA (NTU Singapore), Harvard Certificate in Healthcare Leadership, Post Graduate Diploma in Healthcare Management. Former COO Tan Tock Seng Hospital (SARS period), Ex-CEO NTUC Healthcare, Deputy CEO Richland Logistics (SGX Main board), Deputy CEO, Sensori International (owned OTCBB USA, Hubei Mingkang Pharmaceuticals, China) immediate past member Singapore Parliamentary Committee (Health), past member of Pemandu (Aged care, Kuala Lumpur) and various other senior appointments and board seats in public and private organizations. Adjunct A/P, University of Puthisastra, Cambodia.

Dietrich Joos
details
Dietrich Joos
Chief Finance Officer | Director of the Board ACM Biosciences

Master’s Degree in Economics and Social Sciences. Managing partner of Independent Capital Group, he is a long-term Life Sciences investor with more than 30 years of experience in asset management. He was Senior Portfolio Manager at Roche and Pharma Analyst at UBS.

Pierre Vandepapelière
details
Pierre Vandepapelière
Clinical Advisor

Pharmacologist. Vaccines Expert with more than 30 years of experience of R&D.
Doctorat at the Université catholique de Louvain, Belgium. Leading function at GSK, Abivax, NeoVacs, Imcyse, and Amyl Therapeutics. CEO at Vaccibio Consulting.

Pieter Neels
details
Pieter Neels
Head of Regulatory, Scientific Advisor

Dr Pieter Neels is a native of Belgium where he trained as an MD (University of Antwerp, 1985) and was boarded as a general practitioner. In 1997, he joined the Belgian Ministry of Public Health as a senior evaluator of the clinical part of registration files in the field of cardiology, nephrology, endocrinology (diabetes) etc.
In 2001 he was appointed CPMP member. In 2002 he was asked to take over all Belgian central vaccine rapporteur ships. He was elected vice-chair of Vaccine Working Party, a CHMP workgroup for vaccines for discussion on development and evaluation of registration files for vaccines until June 2013.
WHO has asked Dr Neels to attend many meetings on vaccine development all over the world in order to share the EU regulatory requirements/competence in vaccinology.
Dr Neels is also a member of the worldwide network on vaccine promotion as he is asked to attend the ADVAC course (Foundation Mérieux) and the IABS conferences.
In 2013 Dr Neels was nominated associate Professor at the Namur University for a course in Vaccinology, he retired in 2020.
In June 2013 Dr Neels stepped down from the CHMP and left the Belgian Federal Agency to start his own consultancy company “Vaccine-Advice” in order to be able to support vaccine development in a more efficacious way.
In 2014 Dr Neels was elected board member of IABS-EU and in 2016 he accepted to chair the Human Vaccine Committee of IABS.

Erich Erber
details
Erich Erber
Director of the Board ACM Biolabs

Founder of the Erber Group, an Austrian animal nutrition company (now part of DSM), which consists of more than 50 affiliates in all continents. He is also founder of the SAN Pacific Investments Group. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.

Erich is the key investor representative on ACM Biolabs’ Board of Directors.

Sang Bin Ong
details
Sang Bin Ong
Director of the Board ACM Biolabs

Sang Bin is currently the managing director of Ritz Venture Capital, a Singapore based family fund that focuses in supporting early-stage companies. He has over 30 years of experience in venture investments as well as mentorship within the academic community. With his background in engineering and business, he is a strong supporter of applying cutting edge technology and cultivating talents to address some of the key challenges in the world in the near future.

Manon Cox
details
Manon Cox
Scientific Advisor

Ex-CEO of Protein Sciences, developed first FDA approved protein flu vaccine. Bought by Sanofi for US$650 million and milestones.

Daniel Paris
details
Daniel Paris
Scientific Advisor, Tropical Infectious Diseases Clinician

Medical Director at Swiss Tropical and Public Health Institute. Professor at University of Basel & University of Oxford.

Onur Boyman
details
Onur Boyman
Clinical Immunologist, Scientific Advisor

Professor & Chair, Clinical Immunology, University of Zurich, Director, Department of Immunology, University Hospital Zurich.

Pierre Morgon
details
Pierre Morgon
Market Access and Partnering, Scientific Advisor

30 years of executive, director, investor and mentor experience in the life science industry.

Peter Moran
details
Peter Moran
Corporate Affairs

PhD. Managed the Micro- and Nano-systems group of 50 R&D staff in the Singapore research institute where the polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. Has worked with Dr Nallani on ACM since 2011.

Katherine Schultheis
details
Katherine Schultheis
Head of Discovery Research

Katherine Schultheis joined ACM Biosciences in 2022 as Head of Discovery Research with a strong background of preclinical development of DNA based vaccines and immunotherapeutics. Katherine has more than 10 years of academic and corporate research experience in the fields of infectious diseases, autoimmunity and oncology. She was heading a research team at Inovio Pharmaceuticals in San Diego, California, before moving back to the greater Basel area in 2021. Katherine obtained her Master’s level degree in Biochemistry from University of Potsdam, Germany.

Yvonne Kennedy
details
Yvonne Kennedy
CMC Project Lead

Yvonne has over 30 years’ experience in the biopharmaceutical industry and significant technical, commercial and project management expertise in the development and commercialisation of oral and parenteral small molecule and biological products.
Prior to joining Cilatus, Yvonne was the Vice President of Technical Operations Project Management and Strategy at Horizon Pharma, overseeing all project managers responsible for managing tech transfers for both a number of small molecule oral products and biologics in late-stage development and commercial settings. She was instrumental in developing project planning systems, processes and tools in constantly changing pharmaceutical development and operational environments.
At Alkermes Pharma she was the Senior Director, Head of Project Management, responsible for the planning, budgeting and tracking of development and commercial product support projects at the Athlone facility, Ireland. At Elan Drug Technologies, she held the position of Senior Director, Head of Project Management, and she was responsible for planning, budgeting and tracking of development and commercial product support projects across 3 locations in Ireland and the US.
Yvonne holds a BSc. degree in Biochemistry and Chemistry, and PhD in Endocrinology from University College Dublin.
Since joining Cilatus, Yvonne has been acting as the CMC team leader for a small molecule for a client and she has been engaged in CDMO/CMO searches. For ACM Biosciences Yvonne is the CMC Project Lead.

Daniel Speiser
details
Daniel Speiser
Consultant

Daniel Speiser is a physician-scientist who graduated in 1982 at the University of Zürich, Switzerland.
Subsequently he specialized in basic and clinical immunology at the Universities of Geneva and Toronto. Over many years he was pioneering clinical cancer immunotherapy and translational research at the University Hospital of Lausanne. He continues promoting clinical cancer immunotherapy development and research at the Universities of Lausanne and Bern, in collaboration with academic and industrial specialists.

Michael Mauch
details
Michael Mauch
Head Project Leadership

Master’s Degree in Humanities at University of Stuttgart (Germany). Master’s Degree (MAS) in Marketing and Business Development at University of Basel (CH). Project Manager with more than 20-year experience in R&D pharma and art business.

Ting Yan Aw
details
Ting Yan Aw
Research Associate

Research associate at ACM Biolabs. Obtained a diploma in Molecular Biotechnology in 2012 and Bachelor’s degree in Biological Sciences in 2019 at the Nanyang Technological University.

Suet Li Chew
details
Suet Li Chew
Research Associate

Research associate in ACM Biolabs. Obtained a diploma in Chemical and Biomolecular Engineering in 2015 and Bachelor’s degree with Honours in Chemistry in 2019 at the National University of Singapore.

Teck Wan Chia
details
Teck Wan Chia
Senior Research Associate

Senior research associate at ACM Biolabs. Obtained a bachelor’s degree in Chemistry and Biological Chemistry in 2019 at the Nanyang Technological University.

Jian Hang Lam
details
Jian Hang Lam
Senior Scientist

Jian Hang Lam holds a Ph.D. from the Yong Loo Lin School of Medicine, National University of Singapore. He was trained in pre-clinical dengue vaccine development and gained experience in virology and immunology, with special focus on investigating correlates of protection.

Shaoqiong Liu
details
Shaoqiong Liu
Principal Scientist

Dr. Liu received her PhD in chemical and biomolecular engineering from National University of Singapore (NUS). She has more than 15 years of research and development experience in Biomedical science and Bioengineering. She has generated 5 patents and 42 papers in reputable journals including Nature communications and Advanced Materials.

Ser Yue Loo
details
Ser Yue Loo
Senior Scientist

Ser Yue Loo is a Senior Scientist at ACM Biolabs. Prior to joining ACM Biolabs, Ser Yue carried out her postdoctoral fellowship at Genome Institute of Singapore, where she conducted research on therapeutics for treatment of triple negative breast cancer. Her work led to the successful translation from bench to bedside with the initiation of a clinical trial BEXMET in National Cancer Centre Singapore.
Loo Ser Yue obtained her PhD from Yong Loo Lin School of Medicine at National University of Singapore in 2014.

Karen Ng.
details
Karen Ng.
Admin

A reliable professional with excellent interpersonal, planning and customer service skills to ensure effective operations in the organisation. With 15 years of experience in providing administration, accounts, payroll and program management in the education industry such as SIM, National University of Singapore and Singapore University of Social Sciences.

Esther Ong
details
Esther Ong
Accountant

I joined ACM Biolabs in November 2019 as an Accountant. Prior to this, I worked in a few organisations holding roles as accountant and financial controller . Other than overseeing the regular operation s of a n accounts and finance departme nt, my work typically involve d enhancement and improvement in internal finan c ial systems. A s a manager in Mitsubishi Electric Singapore , I was heavily involved in the development and establishment p rocurement system for the As ia Procurement Centre, using SAP. To better manage cost centres, I helped in the development and establishment of shared services centr e. At Kn owledge Universe , I was involved in the acquisition and merger of local SMEs which resulted in some 700 teachers. My involvement include d preparation and handling of due diligence and legal clearance , and the assimilation of a new parent and siblings at the operational ground level . Arising from the merger of various entities, I lead the integration of the financial systems and establishment of Oracle financial system . Business in a n interestingly challeng ing interplay of human intellects, o pportunities and res ources , facilitated by i ts internal systems . I hope to continue to play a part in some of thes e areas in ACM’s journey into the future.

Henry Cheng
details
Henry Cheng
Accounting

Henry Cheng is an accountancy graduate from NUS (Singapore), holds an MBA (Glasgow University) and CIMA (UK). He has worked with US multinational companies like Rockwell International, Becton Dickinson and RR Donnelley & Sons. Besides manufacturing, he has also worked in the logistics, Online cum Retail business sectors. He used to cover the Asia Pacific region, including involvement in several start-ups.

Sundar Prasanth Authimoolam
details
Sundar Prasanth Authimoolam
Senior Scientist

Experienced Researcher in the areas of Pharmaceutical Formulations and Preclinical Product Development. Doctorate in Chemical Engineering from the University of Kentucky with Post-doctoral experiences from New York University and Singapore-MIT Alliance for Research & Technology, Singapore.

Devendra Shivhare
details
Devendra Shivhare
Scientist

Devendra obtained his bachelor’s degree in Biotechnology from Vellore Institute of Technology and master’s degree in Biotechnology and Biochemical engineering from Indian Institute of Technology. After a brief working experience in India, Devendra decided to pursue higher study and joined Nanyang Technological University, Singapore. In his PhD, he gained significant experience in protein biochemistry. Devendra continued his academic career at NTU as a Post-Doc to study Protein-protein interaction networks.

Gaurav Sinsinbar
details
Gaurav Sinsinbar
Scientist

Gaurav joined ACM Biolabs in 2021, after completing his PhD research in the field of point-of-care diagnostics from the School of Material Science and Engineering at NTU.

Vishwa Prasad Aitha
details
Vishwa Prasad Aitha
Principal Scientist

Vishwa Prasad Aitha is an accomplished scientist with over 20 years of experience in polymer development and commercialization for well-established companies such as Evonik AG, BASF AG, Institute of Chemical and Engineering Sciences and Mitsui Chemicals, Inc. 
He has a proven track record of success developing commercial products from concepts and has demonstrated experience in spearheading large and complex R&D projects throughout its entire lifecycle.
In 1999, Prasad had received his PhD from the National Chemical Laboratory, Pune, India.

Siamy Wong
details
Siamy Wong
Project Manager

Studied Veterinary Microbiology from the Royal Veterinary College, London. Spent more than a decade working in a government animal disease research centre in East Malaysia as a bacteriologist supporting field veterinarians in their diagnosis of livestock diseases. Then she moved on to work in an MNC based in Singapore and spent another 17 years for an animal health related job.

view more

We are looking for highly motivated specialists – take a look at our career offers

Our Pipeline

Discovery
Preclinical Development
Clinical Development
Immuno-Oncology
ACM-005
TLR9 agonist
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III
Planned Investigator Initiated Trial
ACM-004
KRAS cancer vaccine
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III
Phase I grant available
De-novo
(target not disclosed)
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III
Infectious Disease
ACM 006
(target not disclosed)
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III
mRNA program to be announced
ACM-001
SARS-CoV-2 Beta variant vaccine*
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III
Partner needed for Phase 2/3
ACM-002
Corona-Influenza combo
In vitro
In vivo
GLP-Tox
Phase I
Phase II
Phase III

*  Intramuscular and intranasal delivery

Publications

Documented achievements.

News

The news.

Contact.

office@acmbiolabs.com

Contact us for any question in the field of science.

office@acmbiosciences.com

Contact us for any question in the field of investment, studies and business development.

ACM Biolabs Pte Ltd

71 Nanyang Drive, #02M-02 NTU Innovation Centre, Singapore 638075
Phone: +65 6265 5646

ACM Biosciences AG

Steinenberg 1, CH-4051 Basel, Switzerland
Phone: +41 61 975 85 88

Career Offers

We are currently building a high quality and motivated team to bring our COVID 19 vaccine through clinical trials. We are particularly interested in hearing from candidates who specialize in vaccine development, have liposomal or polymersomal formulation experience. Interested applicants should please forward their resumé / CV to career@acmbiolabs.com

career offers